Retatrutide 5mg

Manufacturer: U.S. Made Peptides

Pharmaceutical name: Retatrutide

Pack: 1 vial (5 mg)

Retatrutide (LY3437943) TFA is a peptide that acts as a triple agonist for the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). It inhibits human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643, and 0.775 nM, respectively. Retatrutide TFA is applicable for obesity research.

 

Aside from facilitating weight loss, retatrutide has demonstrated potential in enhancing glycemic control. In 72% of participants, prediabetes reversed to normal glucose levels. The medication also had beneficial effects on cardiovascular health indicators, including notable reductions in both systolic and diastolic blood pressure as well as an improved lipid profile.

 

Mild-to-moderate side effects and drug mechanism

The most frequently reported adverse events were mild-to-moderate gastrointestinal issues, particularly during the dose escalation phase. Researchers believe the drug’s effectiveness stems from its agonistic actions on the glucagon, GIP, and GLP-1 receptors, suggesting the important roles these receptors play in mediating the therapeutic effects of retatrutide.